Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358581 | 1.00 | TSHR (0.43) | TSHRACHECYP3A4TDP1CD44 | |
| Methyl Alcohol SCHEMBL28179894 | 0.95 | ACHE (0.39) | TSHRACHECYP3A4TDP1CD44 | |
| SCHEMBL29468607 | 0.79 | TSHR (0.47) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL235850 | 0.79 | TSHR (0.47) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL8999536 | 0.77 | TSHR (0.45) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL29726981 | 0.77 | TSHR (0.45) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL1642155 | 0.77 | TSHR (0.45) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL6508099 | 0.77 | TSHR (0.45) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL8666802 | 0.75 | TSHR (0.43) | TSHRACHECYP3A4TDP1ALDH1A1 | |
| SCHEMBL20774081 | 0.75 | TSHR (0.43) | TSHRACHECYP3A4TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858658-B2 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090227667-A1 | FLUORO- AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7547725-B2 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH (US) | 2009-06-16 | — | — | US | disclosed |
| WO-2009018280-A2 | SUBSTITUTED INDOLES | AUSPEX PHARAMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-7300951-B2 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070254929-A1 | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| EP-1608638-A1 | FLUORO-AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF | Wyeth (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004092155-A1 | FLUORO-AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF | WYETH (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040198778-A1 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254929-A1 | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | SCN8A, CHD8, CHRNA7 | TSHR 202/4885ACHE 806/4885CYP3A4 2849/4885 |
| US-20090227667-A1 | FLUORO- AND TRIFLUOROALKYL-CONTAINING HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION AND DERIVATIVES THEREOF | SCN8A, CHD8, CDR2 | TSHR 212/4885ACHE 905/4885CYP3A4 2923/4885 |
| US-20040198778-A1 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | BACE1, APP, PSEN1 | TSHR 835/4885ACHE 501/4885CYP3A4 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.